How Does Nash Pass Accelerate
Investigational Drug Clinical Trials?
NASH PASS is a powerful platform to improve enrollment and site selection for NAFLD and NASH clinical trials. The NASH PASS patient registry compiles real-time and longitudinal data for prescreened patients ready for enrollment and prequalified sites ready for an expedited study launch. For study sponsors, the benefits include optimized I/E criteria utilizing a sample data set; streamlined site selection; study start within three months; and front-loaded enrollment for the first three months to significantly improve overall study timelines.
NASH PASS Impact on Timelines, Cost and Enrollment:
vs.
Regulatory
Industry vs. NASHPASS
Typically 6 MONTHS
Often site selection is extended to outside the US for added patient access, increasing cost and time.
1 MONTH utilizing NASH PASS sites in the US, thereby reducing associated regulatory costs.
Study Start
Industry vs. NASHPASS
Site selection alone is generally 4 MONTHS.
Prequalified sites in NASH PASS registry ready for immediate start and all sites screening in < 3 MONTHS.
Enrollment
Industry vs. NASHPASS
DELAYS due to enrollment difficulties and resulting protocol amendments, often to adjust I/E criteria.
Front-load enrollment in first 3 months.
100% ENROLLMENT on time when utilizing NASH PASS for I/E parameters.
